학술논문

Evaluation of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Status Before and After Neoadjuvant Chemotherapy in Breast Cancer Patients
Document Type
Academic Journal
Source
Indian Journal of Surgery. June 2021, Vol. 83 Issue Suppl 2, p399, 5 p.
Subject
Cancer -- Adjuvant treatment
Cancer patients -- Care and treatment
Phenols -- Analysis
Progesterone -- Analysis
Estrogen -- Analysis
Breast cancer -- Care and treatment
Epidermal growth factor -- Analysis
Health
Care and treatment
Analysis
Language
English
ISSN
0972-2068
Abstract
Evaluation of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2/neu) receptor was carried out on 80 breast cancer patients before and after neoadjuvant chemotherapy (NAC). No differences in expression were noted in 89% with reference to ER, 95% with reference to PR, and 91% with reference to HER2/neu status. A change in receptor status from positive to negative was noted in 12% for ER, 5% for PR, and 21% for HER2/neu after NAC. A negative to positive shift was noted in 11% for ER, 4% for PR, and 4% for HER2/neu after NAC. The possible reasons ascribed for change in receptor status after NAC are as follows: (1) Selection of chemoresistant clones with different receptor expression after NAC. (2) Tumor heterogeneity with variable receptor expression in different areas. (3) Ovarian suppression during NAC leading to alteration in receptor expression. (4) Technical considerations such as staining techniques and intra-observer and inter-observer differences in IHC slide interpretation before and after NAC.
Author(s): Adarsh Verma [sup.1], Amrita Ghosh Kar [sup.2], Ram Niwas Meena [sup.1], S. C. U. Patne [sup.2], Shashi Prakash Mishra [sup.1], Seema Khanna [sup.1], Rahul Khanna [sup.1] Author Affiliations: (1) [...]